Northern Trust Corp Has $34.97 Million Position in Ionis Pharmaceuticals Inc (IONS)

Northern Trust Corp lifted its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 1.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 646,790 shares of the company’s stock after buying an additional 6,578 shares during the quarter. Northern Trust Corp’s holdings in Ionis Pharmaceuticals were worth $34,966,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new position in Ionis Pharmaceuticals during the 4th quarter valued at about $968,000. Aviva PLC grew its holdings in Ionis Pharmaceuticals by 3.3% during the 4th quarter. Aviva PLC now owns 207,565 shares of the company’s stock valued at $11,221,000 after purchasing an additional 6,588 shares during the last quarter. Parametrica Management Ltd bought a new position in Ionis Pharmaceuticals during the 4th quarter valued at about $225,000. Commonwealth Equity Services LLC grew its holdings in Ionis Pharmaceuticals by 4.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 18,927 shares of the company’s stock valued at $1,023,000 after purchasing an additional 792 shares during the last quarter. Finally, Castle Rock Wealth Management LLC bought a new position in Ionis Pharmaceuticals during the 4th quarter valued at about $854,000. Institutional investors own 85.05% of the company’s stock.

NASDAQ:IONS opened at $78.90 on Monday. Ionis Pharmaceuticals Inc has a 52 week low of $39.07 and a 52 week high of $81.03. The company has a debt-to-equity ratio of 0.53, a current ratio of 7.88 and a quick ratio of 7.85. The company has a market cap of $10.92 billion, a P/E ratio of 26.66 and a beta of 2.40.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, February 27th. The company reported $2.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $2.20. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. The company had revenue of $192.00 million during the quarter, compared to analysts’ expectations of $159.59 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. Ionis Pharmaceuticals’s revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, equities analysts anticipate that Ionis Pharmaceuticals Inc will post -0.1 EPS for the current fiscal year.

In other Ionis Pharmaceuticals news, SVP Patrick R. O’neil sold 4,400 shares of the company’s stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $54.80, for a total transaction of $241,120.00. Following the transaction, the senior vice president now owns 14,584 shares in the company, valued at approximately $799,203.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph H. Wender sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $79.63, for a total transaction of $796,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 240,397 shares of company stock worth $15,593,408 in the last 90 days. 2.44% of the stock is currently owned by company insiders.

A number of equities analysts have commented on IONS shares. TheStreet upgraded shares of Ionis Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, March 1st. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Wednesday, January 2nd. Morgan Stanley set a $71.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, March 1st. Finally, Piper Jaffray Companies set a $63.00 price target on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $61.38.

ILLEGAL ACTIVITY WARNING: “Northern Trust Corp Has $34.97 Million Position in Ionis Pharmaceuticals Inc (IONS)” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2019/03/25/northern-trust-corp-has-34-97-million-position-in-ionis-pharmaceuticals-inc-ions.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Read More: What is the strike price in options trading?

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.